Investigations Into Sepsis-associated Acute Kidney Injury

Last updated: March 18, 2025
Sponsor: University Hospital of North Norway
Overall Status: Active - Recruiting

Phase

N/A

Condition

Kidney Disease

Kidney Failure

Renal Failure

Treatment

Para Aminohippurate

Clinical Study ID

NCT05694624
Record ID 3055
  • Ages 18-100
  • All Genders

Study Summary

In this study the investigators would like to study systemic and regional disturbances in patients with sepsis-associated acute kidney injury and in healthy controls undergoing laparoscopic abdominal surgery. Specifically study metabolic, hemodynamic and oxygen transport variables.

Eligibility Criteria

Inclusion

Inclusion Criteria sepsis group:

  • Sepsis diagnosed or suspected

  • Normal premorbid serum creatinine measured or anticipated (if data are notavailable)

  • Normovolemia as indicated by a pulse pressure variation less than 12%

Comparator group

  • Previously healthy individuals scheduled for laparoscopic colon cancer resection

  • Normal creatinine levels within 3 months before admittance to hospital.

  • Patients admitted to the intensive care unit with sepsis diagnosed or suspected

  • Previously healthy patients listed for elective colon cancer surgery

Exclusion

Exclusion Criteria:

Study Design

Total Participants: 20
Treatment Group(s): 1
Primary Treatment: Para Aminohippurate
Phase:
Study Start date:
August 14, 2023
Estimated Completion Date:
December 31, 2026

Study Description

Acute kidney injury (AKI) in patients with sepsis has a very poor prognosis with up to 60% mortality. The pathobiology remains to be fully understood. Creatine and phosphocreatine, products of arginine metabolism through L-arginine:glycine amidinotransferase (AGAT) and its sister enzyme guanidinoacetate N-methyl-transferase (GAMT), provide an energy-buffering system that is essential for intracellular adenosine triphosphate (ATP) supply. We hypothesized that sepsis associated AKI may be caused by failure of this energy-buffering system. In series of pilot studies, we explored metabolic and bioenergetic patterns in patients and animals with high risk of developing AKI. These data suggest that sepsis associated AKI may be caused by failure of this alternative renal energy source. In the current application we propose a clinical investigation of renal metabolism and renal bioenergetics in patients with high and low risk of developing sepsis associated AKI. The primary objective is to directly investigate renal AGAT activity through the arginyl metabolites homoarginine, guanidino acetate, and creatine. Secondary objectives are to study renal and systemic hemodynamics, renal oxygenation, glomerular filtration rate (GFR), renal tubular function, and mitochondrial respiration.

Connect with a study center

  • University Hospital of North Norway

    Tromsø, Troms 9038
    Norway

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.